Israel-based BGN Technologies has partnered with Singaporean medical diagnostics maker Biosensorix for the development of next-generation diagnostics for point-of-care.

As part of the partnership, the firm will leverage the research performed at Israeli Ben-Gurion University (BGU), which created an electrochemical lateral flow immunosensor in the form of a smart drive that is similar to a USB.

The sensor has been designed to carry out a quantitative diagnosis of biomarkers and pathogens associated with diseases.

Biosensorix has already developed the technology for the diagnosis of dengue hemorrhagic fever.

The firms are further advancing the sensor to assess stroke severity and identify a secondary stroke early.

They are formulating the new diagnostic kit to analyse a blood sample for specific biomarkers after an ischemic stroke.